| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 08/06/2009 | WO2009055074A8 Erbb2 binding proteins and use thereof |
| 08/06/2009 | WO2009048760A3 Biphenyl inhibitors of carbonyl reductase |
| 08/06/2009 | WO2009043522A3 Use of a peptide as a therapeutic agent |
| 08/06/2009 | WO2009043463A3 Use of gluten exorphin c : as a therapeutic agent |
| 08/06/2009 | WO2009035351A9 Galenic form of drug for treating internal cancerous infections and method for making same |
| 08/06/2009 | WO2009033795A3 Use of a obestatin as a therapeutic agent |
| 08/06/2009 | WO2009033794A3 Use of endothelin-1, optionally in combination with obestatin, as a therapeutic agent |
| 08/06/2009 | WO2009033793A3 Pentagastrin as a therapeutic agent |
| 08/06/2009 | WO2009033721A3 Use of salusin beta alone or in combination with octreotide as a therapeutic agent |
| 08/06/2009 | WO2009004152A3 Use of a composition of oligomers of galacturonic acid as an agent for inhibiting degradation of collagen |
| 08/06/2009 | WO2008150957A3 Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles |
| 08/06/2009 | WO2008132500A3 Chkl inhibitors with b cell depleting antibodies for the treatment of hematologic malignancies |
| 08/06/2009 | WO2008124102A3 Ara-c in combination with a cytokine-secreting cell and use thereof |
| 08/06/2009 | WO2008109532A8 Nucleic acid compounds for inhibiting fas gene expression and uses thereof |
| 08/06/2009 | WO2008109382A8 Nucleic acid compounds for inhibiting pkn3 gene expression and uses thereof |
| 08/06/2009 | WO2008091530A3 Diagnostic and therapeutic cyclooxygenase-2 binding ligands |
| 08/06/2009 | WO2008038127A8 Junctional adhesion molecule-c (jam-c) binding compounds and methods of their use |
| 08/06/2009 | US20090198061 Camptothecin analogs and methods of preparation thereof |
| 08/06/2009 | US20090197965 Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease |
| 08/06/2009 | US20090197949 Antitumor methods and compositions comprising sesquiterpene derivatives |
| 08/06/2009 | US20090197945 Method for Generating Reference Controls for Pharmacogenomic Testing |
| 08/06/2009 | US20090197940 CHONDROPSIN-CLASS ANTITUMOR V-ATPase INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF |
| 08/06/2009 | US20090197938 Polyphenol Type Compounds, Compositions Containing Same and Use Thereof for Preventing or Treating Diseases Involving Abnormal Cell Proliferation |
| 08/06/2009 | US20090197937 Marine actinomycete taxon for drug and fermentation product discovery |
| 08/06/2009 | US20090197936 Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide |
| 08/06/2009 | US20090197913 Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
| 08/06/2009 | US20090197908 Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met |
| 08/06/2009 | US20090197904 Sulphamides for Treatment of Cancer |
| 08/06/2009 | US20090197901 Variolin derivatives and their use as antitumor agents |
| 08/06/2009 | US20090197893 Methods of Identifying and Treating Individuals Exhibiting Complex Karyotypes |
| 08/06/2009 | US20090197889 Synthesis and anti-proliferative effect of benzimidazole derivatives |
| 08/06/2009 | US20090197882 Indazole derivatives for the treatment of hsp90-induced diseases |
| 08/06/2009 | US20090197876 Indolinone derivatives substituted in the 6 position, their preparation and their use as medicaments |
| 08/06/2009 | US20090197870 Pharmaceutical Compositions |
| 08/06/2009 | US20090197866 Pyrazolylbenzimidazole derivatives, compositions containing them and use thereof |
| 08/06/2009 | US20090197864 Furo- and Thieno [3,2-c] Pyridines |
| 08/06/2009 | US20090197863 Benzoxazole carboxamide inhibitors of poly(adp-ribose)polymerase (parp) |
| 08/06/2009 | US20090197861 Inhibitors of integrin alpha2beta1 with modified urea moiety |
| 08/06/2009 | US20090197854 Use of picoplatin to treat colorectal cancer |
| 08/06/2009 | US20090197853 Methods and compositions of treating cancer |
| 08/06/2009 | US20090197848 Synthetic mimics of mammalian cell surface receptors: method and compositions |
| 08/06/2009 | US20090197844 Demethylpenclomedine Analogs and Their Use as Anti-Cancer Agents |
| 08/06/2009 | US20090197835 Vinyl phosphonate lysophosphatidic acid receptor antagonists |
| 08/06/2009 | US20090197833 Silicon Containing Compounds Having Selective Cox-2 Inhibitory Activity and Methods of Making and Using the Same |
| 08/06/2009 | US20090197824 Extended Release Pharmaceutical Formulations of S-Adenosylmethionine |
| 08/06/2009 | US20090197821 Compositions and methods for the delivery of poorly water soluble drugs and methods of treatment |
| 08/06/2009 | US20090197813 Methods for treating FSH related conditions with GnRH antagonists |
| 08/06/2009 | US20090197810 Alpha conotoxin peptides with analgesic properties |
| 08/06/2009 | US20090197798 Synthetic anti-neuropilin 1 (NRP1) cyclic peptide containing RRXR motif |
| 08/06/2009 | US20090197337 Methods for the production of multimeric proteins and related compositions |
| 08/06/2009 | US20090196913 Anti-Alpha-V Immunoliposome Composition, Methods, and Uses |
| 08/06/2009 | US20090196912 Pyridinylamines |
| 08/06/2009 | US20090196887 Immunogenic Compositions for Activating Gamma Delta T Cells |
| 08/06/2009 | US20090196885 Cancer Treatment |
| 08/06/2009 | US20090196880 Cancer treatment using humanized antibodies that bind to EphB4 |
| 08/06/2009 | US20090196876 Novel Gene Disruptions, Compositions and Methods Relating Thereto |
| 08/06/2009 | US20090196871 Use of 4-pyridylmethylphthalazines for cancer treatment |
| 08/06/2009 | US20090196870 Binding constructs and methods for use thereof |
| 08/06/2009 | US20090196869 Antitumor combinations containing taxane derivatives |
| 08/06/2009 | US20090196866 Pharmaceutical composition containing an iron-binding agent |
| 08/06/2009 | US20090196862 High dosage Vitamin D |
| 08/06/2009 | US20090196856 Method for Generating Dendritic Cells Employing Decreased Temperature |
| 08/06/2009 | US20090196850 Anti-Kir Combination Treatments and Methods |
| 08/06/2009 | CA2854933A1 Methods and compositions using soluble klotho proteins |
| 08/06/2009 | CA2714554A1 Vaccine compositions |
| 08/06/2009 | CA2713930A1 Combined use of angiogenesis inhibitor and taxane |
| 08/06/2009 | CA2713813A1 Intralymphatic chemotherapy drug carriers |
| 08/06/2009 | CA2713784A1 Use of amidoxime carboxylic acid esters and n-hydroxyguanidine carboxylic acid esters for producing prodrugs |
| 08/06/2009 | CA2713673A1 Agent for enhancing anti-tumor effect comprising oxaliplatin liposome preparation, and anti-tumor agent comprising the liposome preparation |
| 08/06/2009 | CA2713658A1 Oxim derivatives as hsp90 inhibitors |
| 08/06/2009 | CA2713571A1 Pharmaceutical composition or combination drug |
| 08/06/2009 | CA2713553A1 Pyrazine derivatives and their use as protein kinase inhibitors |
| 08/06/2009 | CA2713469A1 Methods and compositions relating to carcinoma stem cells |
| 08/06/2009 | CA2713459A1 Improved antitumoral treatments |
| 08/06/2009 | CA2713296A1 Method for determination of sensitivity to anti-cancer agent |
| 08/06/2009 | CA2712966A1 Marker for determination of sensitivity to anti-cancer agent |
| 08/06/2009 | CA2712964A1 Tapasin augmentation for enhanced immune response |
| 08/06/2009 | CA2712339A1 Use of aminopeptidase inhibitors or azaindole compounds for preventing or treating cancerous metastases from epithelial origin |
| 08/06/2009 | CA2711995A1 Novel n-(2-amino-phenyl)-amide derivatives |
| 08/06/2009 | CA2711759A1 Pyrazolopyrimidine pi3k inhibitor compounds and methods of use |
| 08/06/2009 | CA2711575A1 Pyrazolopyrimidines, a process for their preparation and their use as medicine |
| 08/06/2009 | CA2711207A1 Recombinant ganoderma lucidium immunomodulatory protein (rlz-8) and uses thereof |
| 08/06/2009 | CA2710929A1 Imidazopyrazines as protein kinase inhibitors |
| 08/05/2009 | EP2085780A2 Methods and products related to low molecular weight heparin |
| 08/05/2009 | EP2085398A1 Pyrazolopyrimidines, a process for their preparation and their use as medicine |
| 08/05/2009 | EP2085391A2 Inhibitors of factor XA and other serine proteases involved in the coagulation cascade |
| 08/05/2009 | EP2085390A1 Labelled analogues of halobenzamides as multimodal radiopharmaceuticals and their precursors |
| 08/05/2009 | EP2085386A2 Pyridinium and quinolinium derivatives as Choline kinase inhibitors |
| 08/05/2009 | EP2085379A1 Arylsulfonamido-substituted hydroxamic acid derivatives |
| 08/05/2009 | EP2085095A1 Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart |
| 08/05/2009 | EP2084540A2 Methods of treating, diagnosing or detecting cancer |
| 08/05/2009 | EP2084163A2 Tetracyclic inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications |
| 08/05/2009 | EP2084161A1 Adenine derivatives as inhibitors of hsp90 for the treatment of cancer |
| 08/05/2009 | EP2084159A1 Pyrido ý2, 3-d¨pyrimidines and their use as kinase inhibitors |
| 08/05/2009 | EP2084147A1 Heterocyclic fxr binding compounds |
| 08/05/2009 | EP2084140A1 Arginine derivatives with np-i antagonistic activity |
| 08/05/2009 | EP2084134A1 Chemical compounds |
| 08/05/2009 | EP2084125A1 Aminobenzocycloheptene derivatives, methods for preparing the same and uses thereof in therapy |
| 08/05/2009 | EP2083868A2 Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies |
| 08/05/2009 | EP2083858A2 Human immune therapies using a cd27 agonist alone or in combination with other immune modulators |